Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Dow
Colorcon
AstraZeneca
Express Scripts

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for SHR-1210

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug SHR-1210: Sponsors, patents, clinical trial progress

SHR-1210 is an investigational drug.

There have been 79 clinical trials for SHR-1210. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2012.

The most common disease conditions in clinical trials are Carcinoma, Esophageal Neoplasms, and Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Sun Yat-sen University, and The First Affiliated Hospital of Zhengzhou University.

There are three US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for SHR-1210
TitleSponsorPhase
A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLCXuanwu Hospital, BeijingPhase 2
A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCCJiangsu HengRui Medicine Co., Ltd.Phase 2
A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCCThe First Affiliated Hospital of Zhengzhou UniversityPhase 2

See all SHR-1210 clinical trials

Clinical Trial Summary for SHR-1210

Top disease conditions for SHR-1210
Top clinical trial sponsors for SHR-1210

See all SHR-1210 clinical trials

US Patents for SHR-1210

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SHR-1210   Start Trial Method of treating pancreatic cancer ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
SHR-1210   Start Trial Combination therapies of HDAC inhibitors and PD-1 inhibitors HUYA Bioscience International, LLC (San Diego, CA)   Start Trial
SHR-1210   Start Trial Methods of treating pancreatic cancer ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SHR-1210

Drugname Country Document Number Estimated Expiration Related US Patent
SHR-1210 Australia 2017283491 2036-06-13   Start Trial
SHR-1210 Brazil 112018075660 2036-06-13   Start Trial
SHR-1210 Canada 3026515 2036-06-13   Start Trial
SHR-1210 China 109562086 2036-06-13   Start Trial
SHR-1210 European Patent Office 3468548 2036-06-13   Start Trial
SHR-1210 Israel 263508 2036-06-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Merck
Baxter
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.